Gastric Cancer in the Era of Precision Medicine

Research output: Contribution to journalReview articlepeer-review

Abstract

Gastric cancer (GC) remains the third most common cause of cancer death worldwide, with limited therapeutic strategies available. With the advent of next-generation sequencing and new preclinical model technologies, our understanding of its pathogenesis and molecular alterations continues to be revolutionized. Recently, the genomic landscape of GC has been delineated. Molecular characterization and novel therapeutic targets of each molecular subtype have been identified. At the same time, patient-derived tumor xenografts and organoids now comprise effective tools for genetic evolution studies, biomarker identification, drug screening, and preclinical evaluation of personalized medicine strategies for GC patients. These advances are making it feasible to integrate clinical, genome-based and phenotype-based diagnostic and therapeutic methods and apply them to individual GC patients in the era of precision medicine.

Original languageEnglish (US)
Pages (from-to)348-358
Number of pages11
JournalCMGH
Volume3
Issue number3
DOIs
StatePublished - May 2017

Keywords

  • Cancer Genomics
  • Gastric Cancer
  • Molecular Classification
  • Preclinical Models

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Gastric Cancer in the Era of Precision Medicine'. Together they form a unique fingerprint.

Cite this